Report Library
All Reports
2015 PCSK9 Inhibitors Pulse
August 19, 2015
Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5-question survey of 23 cardiologists evaluated attitudes
towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha
(AMGN), and how the CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To purchase this survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To purchase this survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Dyslipidemia / Hypercholesterolemia |
Additional Resources: